USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Equity-Based Compensation (Tables)

12 Months Ended

Jan. 03, 2015



2015		$ 7,075
2016		5,841
2017		3,634
2018		938
2019+		379
		$ 17,867

The cost above is expected to be recognized over a weighted-average period of 2.0 years.



	Year ended

	2012	2013	2014

Expected volatility (1)	50.7%	41.9%	40.2%
Risk-free interest rate (2)	0.6%	0.7%	1.2%
Expected life (3)	3.9 yrs.	3.9 yrs.	3.6 yrs.
Expected dividend yield (4)	0.0%	0.0%	0.0%
Weighted-average exercise price (5)	$ 39.41	$ 53.83	$ 60.61

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company’s equity awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at December 28, 2013	1,827	$ 37.37	2.6	$ 74,160
Granted	786	60.61
Exercised	(958)	36.02
Forfeited	(100)	49.01
Expired	-	-

Outstanding at January 3, 2015	1,555	$ 49.20	2.9	$ 82,564

Exercisable at January 3, 2015	67	$ 36.14	2.2	$ 4,444